Literature DB >> 9972971

Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis.

E Taglione1, M L Vatteroni, P Martini, E Galluzzo, F Lombardini, A Delle Sedie, M Bendinelli, G Pasero, W Bencivelli, L Riente.   

Abstract

OBJECTIVE: To study the prevalence of hepatitis C virus (HCV) infection in 2 groups of patients, one group with psoriasis and the other with psoriatic arthritis (PsA).
METHODS: We detected anti-HCV antibodies by ELISA and by a recombinant immunoblot assay (RIBA) in the sera of 50 patients with psoriasis and 50 with PsA. As controls we used a group of 76 patients with rheumatoid arthritis (RA), and referred to data on the prevalence of HCV in the general Italian population.
RESULTS: By ELISA, anti-HCV antibodies were detected in 6/50 (12%) patients with PsA, in 5/50 (10%) patients with psoriasis, and in 4/76 (5.2%) patients with RA. All the reactive PsA and RA sera also tested positive on RIBA, while only 3 of the 5 positive results for sera of patients with psoriasis were confirmed by RIBA. The prevalence of HCV infection in patients with psoriasis was not significantly higher than in controls. In contrast, the rate of HCV infection observed in the 50 patients with PsA was higher than that in the other groups, the difference being statistically significant between patients with PsA and the general population.
CONCLUSION: Our data do not support the hypothesis that HCV infection may play a role in the pathogenesis of psoriasis. On the other hand they show a statistically significant difference between the prevalence of HCV infection in patients with PsA and the general population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9972971

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

Review 2.  Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.

Authors:  Telma Thrastardottir; Thorvardur Jon Love
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

3.  Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom.

Authors:  M H Noe; S K Grewal; D B Shin; A Ogdie; J Takeshita; J M Gelfand
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-06-01       Impact factor: 6.166

4.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

5.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors:  Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

Review 6.  Cutaneous manifestations of hepatitis C in the era of new antiviral agents.

Authors:  Simone Garcovich; Matteo Garcovich; Rodolfo Capizzi; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  World J Hepatol       Date:  2015-11-28

7.  Efficacy and safety of direct-acting antiviral agents when combined with secukinumab.

Authors:  Virginia Martinez-Santana; Esther Rodriguez-Murphy; Alex Smithson; Nuria Miserachs-Aranda; Ruben Del Río-Gil; Inmaculada Torre-Lloverás
Journal:  Eur J Hosp Pharm       Date:  2017-05-20

8.  Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.

Authors:  S Aslanidis; T Vassiliadis; A Pyrpasopoulou; I Douloumpakas; C Zamboulis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 3.650

9.  Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment.

Authors:  Sarah Cassell; Arthur Kavanaugh
Journal:  J Immune Based Ther Vaccines       Date:  2005-09-02

10.  Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient.

Authors:  Christopher H Chu; Charles Davis
Journal:  Drug Saf Case Rep       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.